Group 1 - The company announced a merger agreement with MicroPort CardioFlow CRM Limited and the target company, MicroPort Arrhythmia Management, with a transaction value of $680 million [1][2] - The merger will result in the target company becoming an indirect wholly-owned subsidiary of the company, and its financial performance will be consolidated into the company's financial results [1] - The target company specializes in CRM solutions, providing devices to monitor heart information and manage arrhythmias, including treatments for bradycardia and tachyarrhythmias [1] Group 2 - The board believes the transaction aligns with the company's strategic development, aiming to establish a globally influential cardiac product platform [2] - The merger is expected to create synergies that will diversify and expand the company's existing business, particularly in structural heart disease and CRM solutions [2] - The transaction will enhance the company's R&D capabilities, production capacity, distribution channels, and market expansion efforts [2]

Group 1 - The company, HeartLink Medical-B (02160), announced a merger agreement with MicroPort CardioFlow CRM Limited and the target company, MicroPort Medical (00853), to acquire the target company for a valuation of $680 million [1] - The merger will result in the target company becoming an indirect wholly-owned subsidiary of HeartLink Medical, with its financial performance being consolidated into the group's financial results [1] - The target company specializes in CRM solutions, providing devices to monitor cardiac information and manage arrhythmias, including treatments for bradycardia and tachyarrhythmias [1] Group 2 - The board believes the transaction aligns with the group's strategic development, aiming to establish a globally influential cardiac product platform with a diversified product line [2] - The synergies generated from the transaction are expected to enhance and diversify the existing business, particularly strengthening the group's offerings in structural heart disease and CRM solutions [2] - The merger is anticipated to improve the company's R&D capabilities, production capacity, distribution channels, and market expansion efforts [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 目標公司協定價值為680百萬美元，乃由本公司與目標公司經參考仲量聯行 企業評估及諮詢有限公司進行的估值後公平磋商釐定。 目標集團主要從事CRM業務，專注於管理心律失常的解決方案。其提供監測 患者心臟資訊的設備，以便(1)識別異常的心臟狀況，如心動過緩及快速性心 律失常；以及(2)應用電脈衝和電擊來預防或治療有關異常狀況或提供心臟再 同步化治療。 董事認為，交易符合本集團業務的戰略發展，將有助於本集團建立具備全球 影響力的心臟病產品平台，以提供多元化產品及產品管線，並實現互補協同 效應。交易所產生的有關協同效應將擴大及多元化本集團現有業務，尤其是 ...

中期報告 2025 2025 INTERIM REPORT INTERIM REPORT 2025 中期報告 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 CMY CM MY CY CMY K CardioFlow IR2025 Full Cover V01A_10mm_OP.pdf 1 23/9/2025 下午12:54 目錄 | | | 8 公司資料 10 總裁報告 13 財務摘要 14 管理層討論及分析 30 企業管治及其他資料 56 核數師致董事會的獨立審閱報告 57 綜合損益表 58 綜合損益及其他全面收益表 59 綜合財務狀況表 61 綜合權益變動表 63 簡明綜合現金流量表 64 未經審核中期財務報告附註 釋義及技術詞彙表 | 「4C Medical」 | 指 | 4C Medical Technologies, Inc.，一家根據特拉華州法律註冊成立的公司， | | --- | --- | --- | | | | 主要從事二尖瓣及三尖瓣器械的研發 | | 「AccuSniperTM」 | 指 | AccuSniperTM雙層球囊擴張 ...

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 77,000 shares on September 18, 2025, marking a continuous trend of selling over the past trading days [1] - Over the last 5 trading days, there has been a total net reduction of 215,000 shares, and in the last 20 trading days, the cumulative net reduction reached 2.876 million shares [1] - As of now, southbound funds hold 112 million shares of HeartCare Medical-B, which accounts for 4.63% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products, with operations in both domestic and international markets [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 公司名稱: 微创心通医疗科技有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 截至月份: 2025年8月31日 狀態: 新提交 本月底法定/註冊股本總額： USD 50,000 ...

Summary of Key Points from the Conference Call Company Overview - **Company**: 新通医疗 (Xintong Medical) - **Industry**: Medical Devices, specifically focusing on structural heart disease solutions Financial Performance - **Revenue**: Approximately 230 million, a year-on-year increase of 3% [2][11] - **Net Loss**: Reduced by over 96%, from 57 million in H1 2024 to just over 2 million in H1 2025 [11] - **Operating Loss**: Decreased by 81%, from 36 million to approximately 7 million [11] - **Gross Margin**: Stable at around 70% [11][15] - **Cash Reserves**: Exceeded 1.3 billion, indicating strong operational stability [2][3] Market Performance - **Overseas Revenue Growth**: Increased by over 235%, with the IEM region contributing 62% of overseas income [2][12] - **China Market Position**: Maintained the leading market share with 2,146 implants completed, entering 45 new centers [5][11] - **Product Performance**: The left atrial appendage occluder product, 安可迈 (Anke Mai), achieved 750 implants, with a 107% increase in H1 2025 [6][11] Strategic Initiatives - **Product Development**: Focus on innovative solutions for structural heart disease, with 7 products approved in China and 4 in Europe [7][8] - **Acquisition**: Acquired 51% of Shanghai Zhuoxin to enhance the left atrial appendage occluder business [10] - **Global Expansion**: Plans to deepen global registration and commercialization efforts, targeting Asia, Europe, and the Americas [8][13] Competitive Strategy - **Cost Control**: Implemented strict cost control measures to maintain profitability amidst competitive pressures [5][11] - **Market Penetration**: Increased the number of independent operators and enhanced sales efficiency, with a 26% increase in per capita implant volume [5][11] - **Academic Collaboration**: Engaged in academic exchanges to promote global resource collaboration and expand market reach [4] Future Outlook - **Growth Projections**: Expected to maintain a gross margin of around 70% and reduce operating losses further [15] - **Market Expansion**: Aiming for significant growth in overseas markets, with expectations of doubling overseas revenue [14][19] - **CRM Business Integration**: Anticipated benefits from the strategic restructuring of the CRM business, enhancing product pipeline and global reach [10][16] Regulatory and Clinical Impact - **Clinical Guidelines**: New guidelines from the American College of Cardiology positively influence the demand for left atrial appendage occluders [18] - **Market Penetration**: Current penetration rate for left atrial appendage occlusion in China is approximately 0.34%, with significant growth potential as awareness and technology improve [18] Conclusion - **Overall Performance**: Despite market challenges, the company has demonstrated resilience and strategic foresight, positioning itself for sustainable growth and increased market share in both domestic and international markets [34]

Core Viewpoint - The company reported a revenue of RMB 229.1 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.7%, driven by the global commercialization of VitaFlow Liberty® and Alwide®Plus, which significantly boosted overseas revenue by 235.3% compared to the same period in 2024 [1] Financial Performance - The company recorded a net loss of RMB 2.2 million, a significant reduction from the net loss of RMB 57.8 million for the six months ending June 30, 2024 [1] - The improvement in net loss was attributed to stable growth in revenue and gross profit, enhanced operational efficiency through resource optimization and cost control measures, and income generated from the equity sale of its associate company 4C Medical after completing a Series D financing round [1]

公告称，收入增加主要是由于于报告期内，集团的VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统 在全球商业化方面的持续推进促进了海外收入的大幅增长;及集团的AnchorMan左心耳封堵系统及 AnchorMan左心耳导引系统在中国和海外的商业化进展稳步推进。 心通医疗-B(02160)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入2.29亿元，同比增加 2.67%;公司权益股东应占亏损216.3万元，同比减少96.17%;每股基本亏损0.09分。 ...

Core Viewpoint - The company reported a revenue of 229 million, reflecting a year-on-year increase of 2.67%, while the loss attributable to equity shareholders decreased by 96.17% to 2.163 million [1] Revenue Performance - The increase in revenue is primarily attributed to the ongoing global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, which significantly boosted overseas revenue [1] - The steady progress in the commercialization of the AnchorMan® left atrial appendage occlusion system and the AnchorMan® left atrial appendage guiding system in both China and overseas markets also contributed to revenue growth [1]